Patients of COVID-19, especially those of more vulnerable groups, benefit from the application of chronic treatments often in combination. In serious cases of COVID-19 multi organ failure can result, requiring medication management of multiple drugs like benzodiazepines, anticoagulants, opioids and more. There are over 300 ongoing clinical trials for therapeutic management of COVID-19. With multiple drugs being tested and used in combination it is very likely for drug-drug interactions to occur between medications for treatment and resuscitation and other medications being taken by the patient. In addition, inflammatory effects of COVID-19 can change the pharmacokinetic behavior of drugs being taken. Ultimately it is essential to assess clinically significant drug interactions of medications taken by COVID-19 patients and patients also suffering from other medicated disease states.